	US 12,391,747 B2
	Type XXIII collagen assay
Tina Manon-Jensen, Brøndby (DK); Shu Sun, Farum (DK); Joachim Høg Mortensen, Hundige Strand (DK); and Morten Karsdal, København Ø (DK)
Assigned to Nordic Bioscience A/S, Herlev (DK)
Appl. No. 17/429,046
Filed by Nordic Bioscience A/S, Herlev (DK)
PCT Filed Feb. 6, 2020, PCT No. PCT/EP2020/053000 § 371(c)(1), (2) Date Aug. 6, 2021, PCT Pub. No. WO2020/161242, PCT Pub. Date Aug. 13, 2020.
Claims priority of application No. 1901710 (GB), filed on Feb. 7, 2019.
Prior Publication US 2022/0227848 A1, Jul. 21, 2022
Int. Cl. C07K 16/18 (2006.01); G01N 33/68 (2006.01)

CPC C07K 16/18 (2013.01) [G01N 33/6887 (2013.01); C07K 2317/33 (2013.01); C07K 2317/34 (2013.01); G01N 2333/78 (2013.01); G01N 2800/065 (2013.01)]

10 Claims

1. A monoclonal antibody that specifically recognises and binds to a peptide having the C-terminus amino acid sequence GLPVPGCWHK (SEQ. ID NO: 1); wherein the monoclonal antibody or fragment thereof comprises complementarity-determining regions (CDRs):

	CDR-H1:
	(SEQ. ID NO: 6)
	SYAMS,

	CDR-H2:
	(SEQ. ID NO: 7)
	SISTAGRTYYPDTVR,

	CDR-H3:
	(SEQ. ID NO: 8)
	PDYDYDGYIN,

	CDR-L1:
	(SEQ. ID NO: 9)
	RSSKSLLHSNGVTYLY,

	CDR-L2:
	(SEQ. ID NO: 10)
	QMSNLAS,
	and

	CDR-L3:
	(SEQ. ID NO: 11)
	AQNLELPLT.